Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Ljungman, Per  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Wertheimer T, Dohse M, Afram G, Weber D, Heidenreich M, Holler B, Kattner A-S, Neubauer A, Mielke S, Ljungman P, et al. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. Ann Hematol. 2021.
Müller TR, Sekine T, Trubach D, Niessl J, Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al. Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states. Sci Transl Med. 2023;15(704):eadg9452.
Dahlén T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Strömberg U, Wadenvik H, Dreimane A, Myhr-Eriksson K, Zhao J, et al. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study. Am J Hematol. 2022.
Maeurer M, Magalhaes I, Andersson J, Ljungman P, Sandholm E, Uhlin M, Mattsson J, Ringdén O. Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease. Transplantation. 2014;98(12):e95-e96.
Wedge E, Hansen JWerner, Dybedal I, Creignou M, Ejerblad E, Lorenz F, Werlenius O, Ungerstedt J, Holm MSkov, Nilsson L, et al. Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: Clinical and molecular genetic prognostic factors in a Nordic population. Transplant Cell Ther. 2021.
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
B
Saccardi R, Putter H, Eikema D-J, Busto MPaula, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FAyuketang, Baldomero H, et al. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2023.
Vaht K, Brenner J, Ednersson SBram, Ljungman P, Brune M, Andersson P-O. Bone marrow expression of CD68/CD163 macrophages, IL-17, and FOXP3 cells in aplastic anaemia and their relation to prognosis. Eur J Haematol. 2022.
C
Blennow O, Ljungman P. The challenge of antibiotic resistance in haematology patients. Br J Haematol. 2015.
Luo X-H, Poiret T, Liu Z, Meng Q, Nagchowdhury A, Ljungman P. Corrigendum: Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: impact of CMV infection and leukemia relapse. Front Immunol. 2023;14:1195142.
D
Styczyński J, Tridello G, Koster L, Knelange N, Wendel L, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, et al. Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT. Bone Marrow Transplant. 2023.
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, et al. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2018.
Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, Styczyński J, Ward KN, Cesaro S. Donor CMV status influences the outcome of allogeneic stem cell transplantation; a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014.
E
Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018.
F
Raj K, Eikema D-J, McLornan DP, Olavarria E, Blok H-J, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, et al. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018.
H
Ferrua F, Galimberti S, Courteille V, Slatter MAnne, Booth C, Moshous D, Neven B, Blanche S, Laberko A, Shcherbina A, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC Study. J Allergy Clin Immunol. 2019.
Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, Uggla B, Winiarski J, Ljungman P, Andersson P-O, et al. High graft-versus-host disease-free, relapse/rejection-free survival and similar outcome of related and unrelated allogeneic stem cell transplantation for aplastic anemia - a nationwide Swedish cohort study. Biol Blood Marrow Transplant. 2019.
I
Gao Y, Cai C, Wullimann D, Niessl J, Rivera-Ballesteros O, Chen P, Lange J, Cuapio A, Blennow O, Hansson L, et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity. 2022.
Cesaro S, Tridello G, Knelange NSimone, Blijlevens N, Martin M, Snowden JA, Malladi R, Ljungman P, Deconinck E, Gedde-Dahl T, et al. Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT. Bone Marrow Transplant. 2021.
Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, Ljungman P, Wagner AKathleen, Alici E. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS One. 2019;14(2):e0211927.
L
Einarsdottir S, Sverrisdottir I, Vaht K, Bergström T, Brune M, Andersson P-O, Wenneras C, Ljungman P. Long-term immunity against tetanus and diphtheria after vaccination of allogeneic stem cell transplant recipients. Transplant Cell Ther. 2023.
Cesaro S, Pillon M, Sauer M, Smiers F, Faraci M, de Heredia CDíaz, Wynn R, Greil J, Locatelli F, Veys P, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Tra. Bone Marrow Transplant. 2020.
M
Dalianis T, Eriksson B-M, Felldin M, Friman V, Hammarin A-L, Herthelius M, Ljungman P, Mölne J, Wennberg L, Swartling L. Management of BK-virus infection - Swedish recommendations. Infect Dis (Lond). 2019:1-6.
Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JHenri, et al. Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu. Am J Hematol. 2018.
Brands-Nijenhuis AVM, Labopin M, Schouten HC, Volin L, Socié G, Cornelissen JJ, Huynh A, Ljungman P, Malard F, Esteve J, et al. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission. A retrospective survey on behalf of the ALWP of EBMT. Haematologica. 2015.

Pages